Semaglutide Shows Varied Responses in Diabetes and Obesity Patients

The global prevalence of obesity and type 2 diabetes mellitus (T2DM) is rapidly increasing, with projections indicating 60% of adults over 25 will have obesity by 2050. Glucagon-like-peptide-1 receptor agonists (GLP-1 RAs) like semaglutide have revolutionized treatment for these conditions. However, the extent and characteristics of suboptimal therapeutic responses to semaglutide across diverse patient populations remain underexplored.

The meta-analysis revealed significant variability in patient responses to semaglutide. While the average weight loss was -10.5% (95% CI: -9.8% to -11.2%) and HbA1c (a measure of average blood sugar over 2-3 months) reduction was -1.4% (95% CI: -1.2% to -1.6%), a substantial proportion of patients did not achieve optimal outcomes. Approximately 30% of patients with obesity failed to achieve a 5% body weight reduction, and 20% of T2DM patients did not reach an HbA1c target of <7.0% despite consistent semaglutide treatment. Furthermore, 15% of patients experienced less than 3% weight loss, indicating a significant non-responder subgroup. The study also noted that semaglutide at 1.0 mg weekly for T2DM resulted in an average HbA1c reduction of -1.2%, but 25% of these patients still had HbA1c levels above 7.5%.